BTIG Remains a Buy on MDxHealth S.A. Sponsored ADR (MDXH)

In a report released on October 28, Mark Massaro from BTIG reiterated a Buy rating on MDxHealth S.A. Sponsored ADR (MDXHResearch Report), with a price target of $14.00. The company’s shares closed last Friday at $7.01.

Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, MDxHealth S.A. Sponsored ADR, and Exact Sciences. According to TipRanks, Massaro has an average return of -4.0% and a 40.52% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MDxHealth S.A. Sponsored ADR with a $17.50 average price target.

See the top stocks recommended by analysts >>

Based on MDxHealth S.A. Sponsored ADR’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company’s patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

Read More on MDXH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed